Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination

doi:10.1016/j.ajur.2015.08.003

Asian Journal of Urology, 2015, 2 (4): 187-193 doi: 10.1016/j.ajur.2015.08.003

Asian Focus

Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination

Alvin Lee^a, Sing Joo Chia^b

a Yong Loo Lin School of Medicine, National University of Singapore, Singapore;
b Department of Urology, Tan Tock Seng Hospital, Singapore

Abstract
Related Citation (15)

Download:

HTML

PDF (416KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: Despite being the third commonest cancer in Singaporean men, there is a dearth of basic data on the detection rate of prostate cancer and post-procedure complication rates locally using systematic 12-core biopsy. Our objective is to evaluate prostate cancer detection rates using 12-core prostate biopsy based on serum prostate specific antigen (PSA) levels and digital rectal examination (DRE) findings in Singaporean men presenting to a single tertiary centre. The secondary objective is to evaluate the complication rates of transrectal prostate biopsies.Methods: We retrospectively examined 804 men who underwent first transrectal-ultrasound (TRUS) guided 12-core prostate biopsies from January 2012 to April 2014. Prostate biopsies were performed on men presenting to a tertiary institution when their PSA levels were≥4.0 ng/mL and/or when they had suspicious DRE findings.Results: Overall prostate cancer detection rate was 35.1%. Regardless of DRE findings, patients were divided into four subgroups based on their serum PSA levels: 0-3.99 ng/mL, 4.00 -9.99 ng/mL, 10.00-19.99 ng/mL and≥20.00 ng/mL and their detection rates were 9.5%, 20.9%, 38.4% and 72.3%, respectively. The detection rate of cancer based on suspicious DRE findings alone was 59.2% compared to 36.5% based on serum PSA cut-off of 4.0 ng/mL alone. The post-biopsy admission rate for sepsis was 1.5%.

Key words： Digital rectal examination Oncology Prostate cancer Prostate specific antigen Transrectalultrasound Biopsy

Received: 17 May 2015 Published: 29 October 2015

Corresponding Authors: Sing Joo Chia E-mail: sing_joo_chia@ttsh.com.sg

	Service
	E-mail this article
	Add to citation manager
	E-mail Alert
	Articles by authors
	Alvin Lee
	Sing Joo Chia

TRENDMD:

Cite this article:

Alvin Lee,Sing Joo Chia. Contemporary outcomes in the detection of prostate cancer using transrectal ultrasound-guided 12-core biopsy in Singaporean men with elevated prostate specific antigen and/or abnormal digital rectal examination[J]. Asian Journal of Urology, 2015, 2(4): 187-193.

URL:

http://www.ajurology.com/EN/10.1016/j.ajur.2015.08.003 OR http://www.ajurology.com/EN/Y2015/V2/I4/187

[1]	Singapore cancer registry interim annual registry report 2009-2013, National Registry of Diseases Office.
[2]	Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. Eur J Cancer 2005;41:834-45.
[3]	Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al, editors. SEER cancer statistics review, 1975-2011, National Cancer Institute. Bethesda, MD, http:// seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER website, April 2014.
[4]	Andriole GL, Levin DL, Crawford ED, Gelmann EP, Pinsky PF, Chia D, et al. Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 2005;97:433-8.
[5]	Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-8.
[6]	Chia SE, Lau WK, Cheng C, Chin CM, Tan J, Ho SH. Prostatespecific antigen levels among Chinese, Malays and Indians in Singapore from a community-based study. Asian Pac J Cancer Prev 2007;8:375-8.
[7]	Office for National Statistics (ONS). Cancer survival in England: patients diagnosed 2005-2009 and followed up to 2010. London: ONS; 2011.
[8]	Ng LG, Yip S, Tan PH, Yuen J, Lau W, Cheng C. Improved detection rate of prostate cancer using the 10-core biopsy strategy in Singapore. Asian J Surg 2002;25:238-43.
[9]	Tan HH, Gan E, Rekhraj I, Cheng C, Li MK, Thng P, et al. Use of prostate specific antigen (PSA) and transrectal ultrasound (TRUS) in the diagnosis of prostate cancerea local experience. Ann Acad Med Singap 1995;24:550-6.
[10]	Matlaga BR, Eskew LA, McCullough DL. Prostate biopsy: indications and technique. J Urol 2003;169:12-9.
[11]	Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2031-6.
[12]	Egawa S, Matsumoto K, Yoshida K, Iwamura M, Kuwao S, Koshiba K. Results of transrectal ultrasound-guided biopsies and clinical significance of Japanese prostate cancer. Jpn J Clin Oncol 1998;28:666-72.
[13]	Matsumoto K, Satoh T, Egawa S, Shimura S, Kuwao S, Baba S. Efficacy and morbidity of transrectal ultrasound-guided 12- core biopsy for detection of prostate cancer in Japanese men. Int J Urol 2005;12:353-60.
[14]	Seo HK, Chung MK, Ryu SB, Lee KH. Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study. Urology 2007;70:1109-12.
[15]	Hattangadi JA, Chen MH, D'amico AV. Early detection of highgrade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of
[16]	Gosselaar C, Roobol MJ, Van den bergh RC, Wolters T, Schröder FH. Digital rectal examination and the diagnosis of prostate cancerea study based on 8 years and three screenings within the European randomized study of screening for prostate cancer (ERSPC). Rotterdam Eur Urol 2009;55: 139-46.
[17]	Gosselaar C, Roobol MJ, Roemeling S, Schröder FH. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam. Eur Urol 2008;54:581-8.
[18]	Borden Jr LS, Wright JL, Kim J, Latchamsetty K, Porter CR. An abnormal digital rectal examination is an independent predictor of Gleason 7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. Br J Urol 2007;99:559-63.
[19]	Thompson IM, Ankerst DP, Chi C, Goodman PJ, Tangen CM, Lucia MS, et al. Assessing prostate cancer risk: results from the prostate cancer prevention Trial. J Natl Cancer Inst 2006; 98:529-34.
[20]	Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ. Characteristics of prostate cancer detected by digital rectal examination only. Urology 2007;70:1117-20.
[21]	Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL. Urology 2005;66:803-7.
[22]	Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng/mL or less. J Urol 1999; 161:835-9.
[23]	Fowler Jr JE, Bigler SA, Farabaugh PB, Wilson SS. Prostate cancer detection in black and white men with abnormal digital rectal examination and prostate specific antigen less than 4 ng/mL. J Urol 2000;164:1961-3.
[24]	Schröder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000;163:806-12.
[25]	Shim HB, Lee SE, Park HK, Ku JH. Digital rectal examination as a prostate cancer-screening method in a country with a low incidence of prostate cancer. Prostate Cancer Prostatic Dis 2007;10:250-5.
[26]	Gosselaar C, Roobol MJ, Roemeling S, Van der Kwast TH, Schröder FH. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics. Prostate 2007;67:154-61.
[27]	Vis AN, Hoedemaeker RF, Roobol M, Van der Kwast TH, Schröder FH. Tumor characteristics in screening for prostate cancer with and without rectal examination as an initial screening test at low PSA (0.0-3.9 ng/mL). Prostate 2001;47: 252-61.
[28]	Loeb S, Carter HB, Berndt SI, Ricker W, Schaeffer EM. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011;186:1830-4.
[29]	Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol 2013;64:876-92.
[30]	Nam RK, Saskin R, Lee Y, Liu Y, Law C, Klotz LH, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010;183:963-8.
[31]	Batura D, Gopal Rao G. The national burden of infections after prostate biopsy in England and Wales: a wake-up call for better prevention. J Antimicrob Chemother 2013;68:247-9.
[32]	Gonzalez CM, Averch T, Lee AB, Clemens JQ, Dowling R, Goldman HB, et al. AUA/SUNA white paper on the incidence, prevention and treatment of complications related to prostate needle biopsy. American Urological Association website. http://www.auanet.org/common/pdf/practices-resources/ quality/patient_safety/Prostate-Needle-Biopsy-White-Paper. pdf. [accessed 27.07.15].
[33]	Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013;190:419-26.
[34]	Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59:61-71.
[35]	Moore CM, Robertson NL, Arsanious N, Middleton T, Villers A, Klotz L, et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. Eur Urol 2013;63:125-40.
[36]	Van de ven WJ, Barentsz JO. Prostate cancer: MRI/US-guided biopsyea viable alternative to TRUS-guidance. Nat Rev Urol 2013;10:559-60.
[37]	Pokorny MR, De rooij M, Duncan E, Schröder FH, Parkinson R, Barentsz JO, et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014;66:22-9.
[38]	Ito M, Masuda H, Kawakami S, Fujii Y, Koga F, Saito K, et al. Impact of lower urinary tract symptoms on prostate cancer risk among Japanese men with prostate-specific antigen
[39]	Frånlund M, Carlsson S, Stranne J, Aus G, Hugosson J. The absence of voiding symptoms in men with a prostate-specific antigen (PSA) concentration of≥3.0 ng/mL is an independent risk factor for prostate cancer: results from the Gothenburg randomized screening Trial. BJU Int 2012;110: 638-43.
[40]	Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993;270:860-4.
[41]	Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992;147(3 Pt 2):815-6.
[42]	Liang Y, Ankerst DP, Sanchez M, Leach RJ, Thompson IM. Body mass index adjusted prostate-specific antigen and its application for prostate cancer screening. Urology 2010;76: e1-6.